CCPC issues assessment to Uniphar and NaviCorp in relation to its on-going merger review

September 22, 2022

As part of its merger review process into the proposed acquisition of pharmacy solutions business, NaviCorp Limited (trading as Navi Group), by healthcare services provider, Uniphar PLC, merger notification (M/21/079), the Competition and Consumer Protection Commission (CCPC) has issued an assessment of the proposed acquisition to both parties.

This assessment, which sets out the preliminary views of the CCPC, is not a final determination. The parties can request access to the CCPC’s file. They have 15 working days to respond in writing to the CCPC’s assessment and they may also ask to make oral submissions.

This proposed acquisition was originally notified to CCPC in December 2021.  As part of the proposed acquisition, Uniphar would acquire sole control of NaviCorp Limited and its wholly-owned subsidiaries Thera Pharmaceuticals Limited, CarePlus Pharmacy DAC, TouchPlus Technologies Limited, and Pembroke Healthcare Limited.

The CCPC carried out a preliminary investigation of the proposed acquisition and concluded that a full investigation was required to establish if the proposed acquisition could lead to a substantial lessening of competition in the State.

Based on the timelines as set out in the CCPC’s merger review process, at this stage, it is expected that the investigation will conclude by December 2022. At that time, the outcome of the investigation will be published on A full non-confidential version of the CCPC’s determination will subsequently be published.

As the merger control review is ongoing, no further information or comment can be provided at this time.

Return to News

Haven’t found what you’re looking for?